Quick Answer
Century Therapeutics, Inc. reported Long-Term Debt of $3.74 million for fiscal year 2022.
Century Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2022 | $3.74M | -58.0% |
| 2021 | $8.90M | -7.6% |
| 2020 | $9.64M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2022 | $3.74M | -58.0% | -39.1% |
| September 30, 2022 | $6.14M | — | -27.8% |
| June 30, 2022 | $8.50M | — | -15.1% |
| March 31, 2022 | $10.02M | — | +12.5% |
| December 31, 2021 | $8.90M | — | — |
- Century Therapeutics, Inc. showed a decrease of -58.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2022 period, Century Therapeutics, Inc.’s long-term debt has declined by 61.2% (from $9.64 million to $3.74 million).
- The most recent figure is from Century Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 14, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: